Elevai Labs Inc. Overview
Pro stress-test →Elevai Labs Inc. specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The company develops topical aesthetic skin care cosmetic products for the physician-dispensed market, with a focus on leveraging a proprietary stem cell exosome technology.
Strategic Profile
Pro stress-test →In May 2024, Elevai established two wholly owned subsidiaries—Elevai Biosciences, Inc., and Elevai Skincare, Inc.—transitioning its commercialized exosome skincare brand into Elevai Skincare to enhance focus and market penetration. The company's lead biopharmaceutical asset, EL-22, leverages a first-in-class engineered probiotic approach to address obesity while preserving muscle during weight loss treatments, including GLP-1 receptor agonists.
Competitive Landscape
Pro stress-test →Elevai competes in the medical aesthetics skincare market against established dermatology brands and emerging exosome-based companies. The company's proprietary stem cell exosome technology and physician-dispensed model differentiate it from mass-market skincare competitors. Its emerging biopharmaceutical division positions it in the competitive obesity treatment market alongside GLP-1 developers.
Industry Context
Elevai Labs Inc. operates in Physician-dispensed medical aesthetics skincare.
Key facts
Founded: 2022 · Headquarters: Newport Beach, CA · Employees: N/A · Revenue: N/A · Market cap: N/A